PE20051156A1 - Formulaciones de matriz orales que comprenden licarbazepina - Google Patents
Formulaciones de matriz orales que comprenden licarbazepinaInfo
- Publication number
- PE20051156A1 PE20051156A1 PE2005000316A PE2005000316A PE20051156A1 PE 20051156 A1 PE20051156 A1 PE 20051156A1 PE 2005000316 A PE2005000316 A PE 2005000316A PE 2005000316 A PE2005000316 A PE 2005000316A PE 20051156 A1 PE20051156 A1 PE 20051156A1
- Authority
- PE
- Peru
- Prior art keywords
- hydrophilic
- licarbazepine
- formulations including
- hydrophyl
- matrix formulations
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- BMPDWHIDQYTSHX-UHFFFAOYSA-N licarbazepine Chemical compound C1C(O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 BMPDWHIDQYTSHX-UHFFFAOYSA-N 0.000 title 1
- 239000011159 matrix material Substances 0.000 title 1
- 239000000126 substance Substances 0.000 abstract 2
- ZFXVFMBOFIEPII-UHFFFAOYSA-N 1h-azepine-4-carboxamide Chemical compound NC(=O)C1=CC=CNC=C1 ZFXVFMBOFIEPII-UHFFFAOYSA-N 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 230000003203 everyday effect Effects 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0406379A GB0406379D0 (en) | 2004-03-22 | 2004-03-22 | Organic compounds |
| GB0406738A GB0406738D0 (en) | 2004-03-25 | 2004-03-25 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20051156A1 true PE20051156A1 (es) | 2006-02-13 |
Family
ID=34961345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000316A PE20051156A1 (es) | 2004-03-22 | 2005-03-18 | Formulaciones de matriz orales que comprenden licarbazepina |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20070196488A1 (https=) |
| EP (1) | EP1732519A1 (https=) |
| JP (1) | JP2007529564A (https=) |
| AR (1) | AR048318A1 (https=) |
| AU (1) | AU2005226910B2 (https=) |
| BR (1) | BRPI0509067A (https=) |
| CA (1) | CA2558787A1 (https=) |
| EC (1) | ECSP066860A (https=) |
| IL (1) | IL177826A0 (https=) |
| MA (1) | MA28527B1 (https=) |
| MX (1) | MXPA06010810A (https=) |
| NO (1) | NO20064808L (https=) |
| PE (1) | PE20051156A1 (https=) |
| RU (1) | RU2006137330A (https=) |
| TW (1) | TW200534844A (https=) |
| WO (1) | WO2005092294A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0221956D0 (en) * | 2002-09-20 | 2002-10-30 | Novartis Ag | Organic compounds |
| PE20060124A1 (es) * | 2004-03-22 | 2006-03-07 | Novartis Ag | Tabletas de desintegracion que comprenden licarbazepina |
| EP1879590A1 (en) * | 2005-05-06 | 2008-01-23 | Portela & Ca., S.A. | Eslicarbazepine acetate and methods of use |
| US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
| GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
| US8372431B2 (en) | 2007-10-26 | 2013-02-12 | Bial-Portela & C.A., S.A. | Pharmaceutical composition comprising licarbazepine acetate |
| US9346760B2 (en) | 2011-03-08 | 2016-05-24 | Jubilant Life Sciences Limited | Process for the preparation of (S)-(+)- or (R)-(-)-10-hydroxy dihydrodibenz[B,F]azepines by enantioselective reduction of 10,11-dihydro-10-OXO-5H-dibenz[B,F]azepines and polymorphs thereof |
| EP2498481A1 (en) | 2011-03-09 | 2012-09-12 | Sensirion AG | Mobile phone with humidity sensor |
| JP2013237676A (ja) * | 2013-06-26 | 2013-11-28 | Bial-Portela & Ca Sa | 酢酸エスリカルバゼピン及び使用方法 |
| PT3402488T (pt) | 2015-12-18 | 2022-01-25 | Jubilant Generics Ltd | Formas de dosagem orais sólidas de eslicarbazepina |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5472714A (en) * | 1993-09-08 | 1995-12-05 | Ciba-Geigy Corporation | Double-layered oxcarbazepine tablets |
| US6296873B1 (en) * | 1997-01-23 | 2001-10-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Zero-order sustained release delivery system for carbamazephine derivatives |
| CO4920215A1 (es) * | 1997-02-14 | 2000-05-29 | Novartis Ag | Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones |
| IL125244A (en) * | 1998-07-07 | 2002-12-01 | Yissum Res Dev Co | Pharmaceutical compositions containing low-melting waxes |
| AU2003240654A1 (en) * | 2002-05-31 | 2003-12-19 | Desitin Arzneimittel Gmbh | Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release |
| WO2004014391A1 (en) * | 2002-08-06 | 2004-02-19 | Novartis Ag | Use of carboxamides for the treatment of tinnitus |
| PE20060124A1 (es) * | 2004-03-22 | 2006-03-07 | Novartis Ag | Tabletas de desintegracion que comprenden licarbazepina |
-
2005
- 2005-03-18 AR ARP050101070A patent/AR048318A1/es unknown
- 2005-03-18 PE PE2005000316A patent/PE20051156A1/es not_active Application Discontinuation
- 2005-03-21 WO PCT/EP2005/002988 patent/WO2005092294A1/en not_active Ceased
- 2005-03-21 US US10/598,786 patent/US20070196488A1/en not_active Abandoned
- 2005-03-21 CA CA002558787A patent/CA2558787A1/en not_active Abandoned
- 2005-03-21 EP EP05716261A patent/EP1732519A1/en not_active Withdrawn
- 2005-03-21 JP JP2007504334A patent/JP2007529564A/ja active Pending
- 2005-03-21 RU RU2006137330/15A patent/RU2006137330A/ru not_active Application Discontinuation
- 2005-03-21 BR BRPI0509067-9A patent/BRPI0509067A/pt not_active IP Right Cessation
- 2005-03-21 MX MXPA06010810A patent/MXPA06010810A/es not_active Application Discontinuation
- 2005-03-21 TW TW094108532A patent/TW200534844A/zh unknown
- 2005-03-21 AU AU2005226910A patent/AU2005226910B2/en not_active Expired - Fee Related
-
2006
- 2006-08-31 IL IL177826A patent/IL177826A0/en unknown
- 2006-09-19 EC EC2006006860A patent/ECSP066860A/es unknown
- 2006-10-11 MA MA29380A patent/MA28527B1/fr unknown
- 2006-10-23 NO NO20064808A patent/NO20064808L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005226910B2 (en) | 2009-06-04 |
| ECSP066860A (es) | 2006-11-24 |
| MXPA06010810A (es) | 2006-12-15 |
| IL177826A0 (en) | 2006-12-31 |
| NO20064808L (no) | 2006-12-15 |
| JP2007529564A (ja) | 2007-10-25 |
| AU2005226910A1 (en) | 2005-10-06 |
| EP1732519A1 (en) | 2006-12-20 |
| WO2005092294A1 (en) | 2005-10-06 |
| US20070196488A1 (en) | 2007-08-23 |
| RU2006137330A (ru) | 2008-05-10 |
| MA28527B1 (fr) | 2007-04-03 |
| CA2558787A1 (en) | 2005-10-06 |
| AR048318A1 (es) | 2006-04-19 |
| TW200534844A (en) | 2005-11-01 |
| BRPI0509067A (pt) | 2007-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2009000035A1 (es) | Compuestos derivados 3-espiro-heterociclo-1il-5h-ciclopentan[d]pirimidin-indol, util para inhibir la actividad de akt quinasa; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades tal como cancer, fibrosis quistica, diabetes, enfermedad de alzheimer, entre otras. | |
| GT199900203A (es) | Composiciones de celecoxib. | |
| AR045972A1 (es) | Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas | |
| MA28921B1 (fr) | Derive heterocyclique azote et medicament le contenant en tant que principe actif | |
| ECSP066365A (es) | Anilino purinas sustituidas en la posición 6 útiles como inhibidores de rtk | |
| MX2009002196A (es) | Oblea de buprenorfina para terapia de sustitucion de farmacos. | |
| CY1118179T1 (el) | Φαρμακευτικη συνθεση | |
| CL2008001820A1 (es) | Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer. | |
| DE50005529D1 (de) | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac | |
| EP1543158A4 (en) | REGULATED APTAMER THERAPEUTICS | |
| CL2011002766A1 (es) | Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras. | |
| PE20051156A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
| ATE543491T1 (de) | Kombinationspräparat enthaltend ibuprofen und paracetamol | |
| AR054249A1 (es) | Tratamiento de enfermedades del tejido conectivo de la piel | |
| DE60102590T2 (de) | Darreichungsformen zur behandlung von oralen mykosen | |
| AR001765A1 (es) | Una formulación de liberación prolongada un procedimiento para su preparación una forma cristalina de cisaprida-(l)-tartrato y un medicamento util para el tratamiento de trastornos gastrointestinales | |
| CL2002001701A1 (es) | Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno. | |
| UA89753C2 (ru) | Применение модафинила и антидепрессанта при лечении депрессии и для сокращения времени до начала действия антидепрессанта | |
| PE20061051A1 (es) | Composicion farmaceutica que comprende mirtazapina s | |
| BR0015781A (pt) | Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea | |
| SE0203817D0 (sv) | New composition | |
| AR023763A1 (es) | Agente que potencia la liberacion de acetilcolina en el cerebro | |
| ATE332141T1 (de) | Verwendung von 5-substituierten nukleosiden und/oder deren prodrugs zur resistenzfreien therapie von infektionskrankheiten | |
| ATE402703T1 (de) | Tablette enthaltend efletirizin und pseudoephedrin | |
| DE60327249D1 (de) | Anthranilsäureamide und ihre pharmazeutische verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |